1) population pharmacodynamics
群体药效动力学
1.
OBJECTIVE To analyze population pharmacodynamics of propofol in neurosurgical patients and to discuss the influences of the age, weight or gender on the propofol pharmacodynamics.
目的考察脑外科病人丙泊酚的群体药效动力学特征,以及年龄、体重或性别等固定效应对丙泊酚药效动力学的影响。
2) Population pharmacokinetics
群体药代动力学
1.
Population pharmacokinetics of paeoniflorin in guanxin Ⅱ prescription;
冠心Ⅱ号方中芍药苷的群体药代动力学(英文)
2.
Population pharmacokinetics of lamotrigine in Chinese children with epilepsy;
癫癎儿童拉莫三嗪的群体药代动力学研究
3.
Advances in studies on population pharmacokinetics of antiepileptic drugs and CYP450 gene polymorphisms;
抗癫痫药的群体药代动力学与CYP450基因多态性的研究进展
3) Population pharmacokinetics
群体药物动力学
1.
The goal of this study is to investigate the population pharmacokinetics of oral tacrolimus in Chinese renal transplant patients and to identify possible relationship between covariates and population parameters.
本研究旨在考察口服他克莫司(tacrolimus)在中国肾移植患者中的群体药物动力学特征并探讨群体药物动力学参数和相关因素间的关系。
2.
The traditionary methods to estimate population pharmacokinetics parameters must depend on the existing models, which has the objections of heavy workload and many jamming factors.
[目的]群体药物动力学可运用经典药物动力学基本原理结合统计学方法来定量描述患者群体内所存在的药物动力学参数差异,有利于指导临床用药。
3.
The goal of this study is to investigate the population pharmacokinetics of oral given clozapine in Chinese schizophrenic patients and to identify possible relationships between population parameters and covariates including demography factors and CYP1A2 genetic polymorphism,so as to create the population pharmacokinetics model to guide individual clinical delivery.
本研究旨在考察口服氯氮平(clozapine)在中国精神分裂症患者中的群体药物动力学特征,探讨各项动力学参数与人口统计学因素及CYP1A2酶基因多态性的关系,通过建立群体药物动力学模型指导临床个体化给药。
4) PPK
群体药物动力学
1.
Individualized high-dose methotrexate dosing in childhood acute lymphoblastic leukemia with PPK method;
用群体药物动力学方法指导个体化大剂量甲氨蝶呤用药
5) population pharmacokinetic
群体药物代谢动力学
6) Population pharmacokinetics
群体药动学
1.
Population pharmacokinetics of norvancomycin;
去甲万古霉素群体药动学研究
2.
Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukemia;
大剂量甲氨蝶呤在急性淋巴细胞白血病患儿中的群体药动学
3.
Population pharmacokinetics of phenytoin in pediatric patients;
儿童苯妥因群体药动学研究
补充资料：药效动力学缺陷
分子式：
CAS号：
性质：系指因效应器官、组织细胞或受体的遗传学缺陷，使肌体对药物的反应产生量或质上的缺陷。
CAS号：
性质：系指因效应器官、组织细胞或受体的遗传学缺陷，使肌体对药物的反应产生量或质上的缺陷。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条